GT Biopharma, Inc. (GTBP)
NASDAQ: GTBP · Real-Time Price · USD
0.4670
-0.0110 (-2.30%)
At close: Mar 2, 2026, 4:00 PM EST
0.4610
-0.0060 (-1.28%)
After-hours: Mar 2, 2026, 7:38 PM EST
GT Biopharma Employees
GT Biopharma had 1 employees as of December 31, 2024. The number of employees decreased by 1 or -50.00% compared to the previous year.
Employees
1
Change (1Y)
-1
Growth (1Y)
-50.00%
Revenue / Employee
n/a
Profits / Employee
-$34,449,000
Market Cap
12.45M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 1 | -1 | -50.00% | 1 | 0 |
| Dec 31, 2023 | 2 | 0 | - | 2 | 0 |
| Dec 31, 2022 | 2 | -6 | -75.00% | 2 | 0 |
| Dec 31, 2021 | 8 | 5 | 166.67% | 8 | 0 |
| Dec 31, 2020 | 3 | 1 | 50.00% | 3 | 0 |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| CytoMed Therapeutics | 43 |
| BioLineRx | 28 |
| Longeveron | 25 |
| Moleculin Biotech | 17 |
| Quantum BioPharma | 17 |
| Soligenix | 16 |
| NewcelX | 15 |
| Cellectar Biosciences | 11 |
GTBP News
- 17 hours ago - GT Biopharma Reports Full Year 2025 Financial Results - GlobeNewsWire
- 13 days ago - GT Biopharma to Present at the Centurion One Capital 9th Annual Toronto Growth Conference - GlobeNewsWire
- 27 days ago - GT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-5550 TriKE®, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors Expressing B7-H3 - GlobeNewsWire
- 6 weeks ago - GT Biopharma Announces IND Submission for GTB-5550 TriKE®, a B7-H3-targeted natural killer (NK) cell engager for B7-H3 expressing solid tumor cancers - GlobeNewsWire
- 6 weeks ago - EXCLUSIVE: GT Biopharma Plans 2026 Trial For New Cancer Treatment - Benzinga
- 2 months ago - Immunotherapies Replacing Chemotherapy as Blood Cancer Market to Hit $13B by 2030 - PRNewsWire
- 3 months ago - GT Biopharma, Inc. (NASDAQ:GTBP) Offers Near-Term Catalyst Opportunity with Advancing Phase 1 Trials - Accesswire
- 3 months ago - GT Biopharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire